# US 2008/0187968 A1 · Emulsion compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187968 A1
- Document ID: US20080187968A1
- Status: Published application
- Kind: A1
- Application number: 12/079,834
- Filed: 2008-03-28
- Published: 2008-08-07
- Earliest claimed: 2001-11-16
- Assignees: Medical Research Council
- Inventors: Phillip Holliger; Farid Ghadessy
- Web page: https://patentgrep.com/patent/US20080187968A1

## CPC

- C12N 15/1075: {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- C12Q 1/6844: Nucleic acid amplification reactions
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of obtaining a gene product comprising:
forming an emulsion comprising a surfactant, a hydrophobic phase and a hydrophilic phase comprising a plurality of microcapsules containing a functional in vitro eukaryotic expression system, wherein the surfactant is a chemically inert silicone-based surfactant, allowing the gene product to be expressed by the expression system and, optionally, purifying the gene product.

### Claim 24 (depends on 23)

The method of claim 23, wherein the silicone-based surfactant is a silicone copolymer.

### Claim 25 (depends on 24)

The method of claim 24, wherein, the silicone-based surfactant is polysiloxane-polycetyl-polyethylene glycol copolymer.

### Claim 26 (depends on 23)

The method of claim 23, wherein the surfactant is provided at a v/v concentration in the oil phase of 4%.

### Claim 27 (depends on 23)

The method of claim 23, wherein the emulsion comprises an in vitro eukaryotic expression system.

### Claim 28 (depends on 27)

The method of claim 27, wherein the eukaryotic expression system comprises all or part of a mammalian cell lysate.

### Claim 29 (depends on 28)

The method of claim 28, wherein the lysate is a reticulocyte lysate.

### Claim 30 (depends on 28)

The method of claim 28, wherein the lysate is a rabbit reticulocyte lysate.

### Claim 31 (depends on 23)

The method of claim 23, wherein the expression and/or the activity of the gene product within the emulsion is at a level of at least 1% of that of the gene product achievable by the expression system prior to formation of the emulsion.

### Claim 32 (depends on 31)

The method of claim 31 wherein the expression and/or the activity of the gene product within the emulsion is at a level of at least 10%, at least 20%, or at least 30% of that of the gene product achievable with the expression system prior to formation of the emulsion.

### Claim 33 (depends on 23)

The method of claim 23 wherein the emulsion is stable during incubation at 30° C. for at least one hour.

### Claim 34 (depends on 23)

The method of claim 23, wherein the hydrophobic phase comprises a mineral oil.
